The global cell therapy landscape comprises hundreds of active enterprises ranging from early-stage research startups to massive multinational pharmaceutical corporations. Industry databases and biotech mapping platforms track well over five hundred specialized entities globally that focus on developing CAR-T therapies, stem cell treatments, gene-edited cellular medicines, and immunotherapies for oncology and autoimmune diseases. These companies operate across major biotech clusters in North America, Europe, and Asia, continuously advancing clinical pipelines and competing in a rapidly evolving medical technology sector.